Preoperative Prediction of Cholangiocyte Phenotype Hepatocellular Carcinoma on Contrast-enhanced MRI and the Prognostic Implication After Hepatectomy

Overview

Journal Insights Imaging

Publisher Springer

Specialty Radiology

Date 2023 Nov 14

PMID 37962669

Authors

Yidi Chen

Jie Chen

Chongtu Yang

Yuanan Wu

Hong Wei

Ting Duan

Zhen Zhang

Liling Long

Hanyu Jiang

Bin Song

Affiliations

Soon will be listed here.

Abstract

Background: Hepatocellular carcinoma (HCC) expressing cytokeratin (CK) 7 or CK19 has a cholangiocyte phenotype that stimulates HCC proliferation, metastasis, and sorafenib therapy resistance This study aims to noninvasively predict cholangiocyte phenotype-positive HCC and assess its prognosis after hepatectomy.

Methods: Between January 2010 and May 2022, preoperative contrast-enhanced MRI was performed on consecutive patients who underwent hepatectomy and had pathologically confirmed solitary HCC. Two abdominal radiologists separately assessed the MRI features. A predictive model for cholangiocyte phenotype HCC was created using logistic regression analysis and five-fold cross-validation. A receiver operating characteristic curve was used to calculate the model performance. Kaplan-Meier and log-rank methods were used to evaluate survival outcomes.

Results: In total, 334 patients were included in this retrospective study. Four contrast-enhanced MRI features, including "rim arterial phase hyperenhancement" (OR = 5.9, 95% confidence interval [CI]: 2.9-12.0, 10 points), "nodule in nodule architecture" (OR = 3.5, 95% CI: 2.1-5.9, 7 points), "non-smooth tumor margin" (OR = 1.6, 95% CI: 0.8-2.9, 3 points), and "non-peripheral washout" (OR = 0.6, 95% CI: 0.3-1.0, - 3 points), were assigned to the cholangiocyte phenotype HCC prediction model. The area under the curves for the training and independent validation set were 0.76 and 0.73, respectively. Patients with model-predicted cholangiocyte phenotype HCC demonstrated lower rates of recurrence-free survival (RFS) and overall survival (OS) after hepatectomy, with an estimated median RFS and OS of 926 vs. 1565 days (p < 0.001) and 1504 vs. 2960 days (p < 0.001), respectively.

Conclusions: Contrast-enhanced MRI features can be used to predict cholangiocyte phenotype-positive HCC. Patients with pathologically confirmed or MRI model-predicted cholangiocyte phenotype HCC have a worse prognosis after hepatectomy.

Critical Relevance Statement: Four contrast-enhanced MRI features were significantly associated with cholangiocyte phenotype HCC and a worse prognosis following hepatectomy; these features may assist in predicting prognosis after surgery and improve personalized treatment decision-making.

Key Points: • Four contrast-enhanced MRI features were significantly associated with cholangiocyte phenotype HCC. • A noninvasive cholangiocyte phenotype HCC predictive model was established based on MRI features. • Patients with cholangiocyte phenotype HCC demonstrated a worse prognosis following hepatic resection.

Citing Articles

Radiomics predicting immunohistochemical markers in primary hepatic carcinoma: Current status and challenges.

Yin Y, Zhang W, Chen Y, Zhang Y, Shen X Heliyon. 2024; 10(23):e40588.

PMID: 39660185 PMC: 11629216. DOI: 10.1016/j.heliyon.2024.e40588.

References

Wang H, Yang C, Zeng M, Rao S, Ji Y, Weng X . Magnetic resonance texture analysis for the identification of cytokeratin 19-positive hepatocellular carcinoma. Eur J Radiol. 2019; 117:164-170. DOI: 10.1016/j.ejrad.2019.06.016. View

Chernyak V, Fowler K, Kamaya A, Kielar A, Elsayes K, Bashir M . Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology. 2018; 289(3):816-830. PMC: 6677371. DOI: 10.1148/radiol.2018181494. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Roskams T . Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene. 2006; 25(27):3818-22. DOI: 10.1038/sj.onc.1209558. View

Lu X, Xi T, Lau W, Dong H, Zhu Z, Shen F . Hepatocellular carcinoma expressing cholangiocyte phenotype is a novel subtype with highly aggressive behavior. Ann Surg Oncol. 2011; 18(8):2210-7. DOI: 10.1245/s10434-011-1585-7. View

Moons K, Altman D, Reitsma J, Ioannidis J, Macaskill P, Steyerberg E . Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015; 162(1):W1-73. DOI: 10.7326/M14-0698. View

Roskams T . Different types of liver progenitor cells and their niches. J Hepatol. 2006; 45(1):1-4. DOI: 10.1016/j.jhep.2006.05.002. View

Choi S, Kim S, Park C, Min J, Lee J, Choi Y . Imaging Features of Gadoxetic Acid-enhanced and Diffusion-weighted MR Imaging for Identifying Cytokeratin 19-positive Hepatocellular Carcinoma: A Retrospective Observational Study. Radiology. 2017; 286(3):897-908. DOI: 10.1148/radiol.2017162846. View

Liang Y, Xu F, Guo Y, Lai L, Jiang X, Wei X . Diagnostic performance of LI-RADS for MRI and CT detection of HCC: A systematic review and diagnostic meta-analysis. Eur J Radiol. 2020; 134:109404. DOI: 10.1016/j.ejrad.2020.109404. View

10.

Lee T, Guan X, Ma S . Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications. Nat Rev Gastroenterol Hepatol. 2021; 19(1):26-44. DOI: 10.1038/s41575-021-00508-3. View

11.

Yang X, Kong F, Qi L, Lin J, Yan Q, Loong J . PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma. Mol Cancer. 2021; 20(1):20. PMC: 7824946. DOI: 10.1186/s12943-021-01315-9. View

12.

Wang W, Gu D, Wei J, Ding Y, Yang L, Zhu K . A radiomics-based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid-enhanced MRI. Eur Radiol. 2020; 30(5):3004-3014. DOI: 10.1007/s00330-019-06585-y. View

13.

Kang H, Kim H, Lee D, Hur B, Hwang Y, Suh K . Gadoxetate-enhanced MRI Features of Proliferative Hepatocellular Carcinoma Are Prognostic after Surgery. Radiology. 2021; 300(3):572-582. DOI: 10.1148/radiol.2021204352. View

14.

Rhee H, An C, Kim H, Yoo J, Park Y, Kim M . Hepatocellular Carcinoma with Irregular Rim-Like Arterial Phase Hyperenhancement: More Aggressive Pathologic Features. Liver Cancer. 2019; 8(1):24-40. PMC: 6388566. DOI: 10.1159/000488540. View

15.

Lee S, Kang T, Song K, Lee M, Rhim H, Lim H . Effect of Microvascular Invasion Risk on Early Recurrence of Hepatocellular Carcinoma After Surgery and Radiofrequency Ablation. Ann Surg. 2019; 273(3):564-571. DOI: 10.1097/SLA.0000000000003268. View

16.

Chernyak V, Tang A, Flusberg M, Papadatos D, Bijan B, Kono Y . LI-RADS ancillary features on CT and MRI. Abdom Radiol (NY). 2017; 43(1):82-100. DOI: 10.1007/s00261-017-1220-6. View

17.

Jeong H, Kim M, Kim Y, Park Y, Choi G, Choi J . MRI features of hepatocellular carcinoma expressing progenitor cell markers. Liver Int. 2011; 32(3):430-40. DOI: 10.1111/j.1478-3231.2011.02640.x. View

18.

Choi J, Lee J, Sirlin C . CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology. 2014; 273(1):30-50. PMC: 4263770. DOI: 10.1148/radiol.14132362. View

19.

Tovar V, Cornella H, Moeini A, Vidal S, Hoshida Y, Sia D . Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. Gut. 2015; 66(3):530-540. PMC: 5600200. DOI: 10.1136/gutjnl-2015-309501. View

20.

Chen J, Wu Z, Xia C, Jiang H, Liu X, Duan T . Noninvasive prediction of HCC with progenitor phenotype based on gadoxetic acid-enhanced MRI. Eur Radiol. 2019; 30(2):1232-1242. DOI: 10.1007/s00330-019-06414-2. View